(Q41482096)

1 October 2017

1 reference

title

Hyperfractionation: where do we stand? (English)

1 reference

Hans-Peter Beck-Bornholdt

1 October 2017

author

series ordinal

1

object named as

Beck-Bornholdt HP

1 reference

1 October 2017

Dubben HH

2

1 reference

1 October 2017

Liertz-Petersen C

series ordinal

3

1 reference

1 October 2017

Willers H

series ordinal

4

1 reference

1 October 2017

publication date

1 April 1997

1 reference

Radiotherapy and Oncology

1 October 2017

published in

1 reference

1 October 2017

volume

43

1 reference

1 October 2017

issue

1

1 reference

1 October 2017

page(s)

1-21

1 reference

The effect of the overall treatment time of fractionated irradiation on the tumor control probability of a human soft tissue sarcoma xenograft in nude mice

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Multiple daily fractionation in radiotherapy: Biological rationale and preliminary clinical experiences

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Fractionation Scheme with Low Individual Doses in Irradiation of Carcinoma of the Mouth

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Experimental radiotherapy of a rat rhabdomyosarcoma with 15 meV neutrons and 300 kV x-rays. II. Effects of ractionated treatments, applied five times a week for several weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Kinetics of cellular inactivation by fractionated and hyperfractionated irradiation in Lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Radiotherapy of the rhabdomyosarcoma R1H of the rat: hyperfractionation--126 fractions applied within 6 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Influence of treatment time on the response of rat rhabdomyosarcoma R1H to fractionated irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Potential pitfalls in the use of p-values and in interpretation of significance levels

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Rebuttal: is gambling a serious alternative to evidence-based medicine?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Relationship between early and late normal-tissue injury after postmastectomy radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Radiobiological considerations in the design of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment ... now!

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Dose-response relationships for late radiation effects in the head and neck: Regarding the analysis of the RTOG 8313 trial, fu et al IJROBP 32:577–588; 1995

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

The Evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Analysis of the probability and risk of cause-specific failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

In response to bentzen et al., IJROBP 32:1531–1534; 1995

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Improved survival of patients with unresectable non-small-cell bronchogenic carcinoma by an innovated high-doseEn-Bloc radiotherapeutic approach

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-sm

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Five-year survival after hyperfractionated radiation therapy for non-small-cell carcinoma of the lung (NSCCL): results of RTOG protocol 81-08.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Hyperfractionated radiation in children with rhabdomyosarcoma—Results of an intergroup rhabdomyosarcoma pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Super fractionation in glioblastoma multiforme-results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Influence of the timing of a concomitant boost during fractionated irradiation of rat rhabdomyosarcoma R1H

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Irradiation therapy with multiple small fractions per day in urinary bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Hyperfractionated radiation therapy for brain-stem glioma: a phase I-II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Dose, time and fractionation: A clinical hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Stage III ovarian carcinoma: an analysis of treatment results and complications following hyperfractionated abdominopelvic irradiation for salvage

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

The Cure of Rhabdomyosarcoma BA 1112 with Fractionated Radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Preliminary results of a hyperfractionated dose escalation study for locally advanced adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Fractionation and dose-rate. II. Dose-time relationships in radiotherapy and the validity of cell survival curve models

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Relative effectiveness of 12-hourly fractionation and a non-uniform X-ray schedule in the optimum fractionation of C3H mouse mammary tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Optimum fractionation of the C3H mouse mammary carcinoma using x-rays, the hypoxic-cell radiosensitizer Ro-07-0582, or fast neutrons

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Hyperfractionated radiotherapy in brain stem tumors: results of a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Hyperfractionated radiation therapy in brain stem tumors. Results of treatment at the 7020 cGy dose level of Pediatric Oncology Group study #8495.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Late effects of hyperfractionated radiotherapy for head and neck cancer—In response to Drs. Withers and Taylor, IJROBP 32:887–888; 1995

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Misonidazole combined with hyperfractionation in the management of malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: a comparison of two fractionation schedules

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Effects of irradiation by single or multiple fractions per day on transplantable murine mammary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

European Organization for Research on Treatment of Cancer trials using radiotherapy with multiple fractions per day. A 1978-1987 survey

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Hyperfractionated compared with conventional radiotherapy in oropharyngeal carcinoma: an EORTC randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

What has radiation biology contributed to the evolution of radiotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Preliminary results using twice-a-day fractionation in the radiotherapeutic management of advanced cancers of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III nonsmall cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Changes in Mouse Blood Pressure, Tumor Blood Flow, and Core and Tumor Temperatures following Nembutal or Urethane Anesthesia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

The use of 'top-up' experiments to investigate the effect of very small doses per fraction in mouse skin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Renal damage in the mouse: the effect of d(4)-Be neutrons

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Renal Damage in the Mouse: The Response to Very Small Doses per Fraction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

The effect of anaesthesia on the radiosensitivity of rat intestine, foot skin and R-1 tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Radiotherapy of the rhabdomyosarcoma R1H of the rat: influence of the time interval between two daily fractions during hyperfractionated radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Twice-daily fractionation of external irradiation with brachytherapy in bulky carcinoma of the cervix. Phase I/II study of the Radiation Therapy Oncology Group 88-05

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Solid tumor models for the assessment of different treatment modalities: XXV. Comparison of the effect of one radiation fraction per day with multiple fractions per day (MFD) given either continuously or intermittently on tumor response and normal t

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Onc

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Radiation therapy for advanced head and neck squamous-cell carcinoma using twice-a-day fractionation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Twice-daily fractionation schemes for advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Time-dose relationships for the cure of an experimental rat tumor with fractionated radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Rapid hyperfractionated radiotherapy. Clinical results in 178 advanced squamous cell carcinomas of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Analysis of late complications after rapid hyperfractionated radiotherapy in advanced head and neck cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

About tolerance and quality. An important notice to all radiation oncologists

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Results of a pilot study of hyperfractionated radiation therapy for children with brain stem gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. A Childrens Cancer Group Phase I/II Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Hyperfractionated radiotherapy with or without misonidazole: results of a prospective randomized study in stage III-IV squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Results of twice-a-day irradiation of squamous cell carcinomas of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Hyperfractionation for head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Twice-a-day radiotherapy for squamous cell carcinoma of the head and neck: the University of Florida experience

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Malignant astrocytoma. Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Mechanical assay of consequential and primary late radiation effects in murine small intestine: alpha/beta analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Radiotherapy with thrice-a-day fractionation in a short overall time: Clinical experiences

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

A Multicomponent X-ray Survival Curve for Mouse Lymphosarcoma Cells irradiated in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Multiple fractions per day in retrospect; the L-Q model and the tolerance profile

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

High dose hyperfractionated radiotherapy in the treatment of extremity soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Effect of normobaric oxygen on tumor radiosensitivity: fractionated studies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Extrapolations from laboratory and preclinical studies for the use of carbogen and nicotinamide in radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Enhancement of tumor radiosensitivity and reduced hypoxia-dependent binding of a 2-nitroimidazole with normobaric oxygen and carbogen: a therapeutic comparison with skin and kidneys

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Should carbogen and nicotinamide be given throughout the full course of fractionated radiotherapy regimens?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Is hyperfractionation really better?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Hyperfractionation in the radiation therapy of unresectable non-oat cell carcinoma of the lung: preliminary report of a RTOG Pilot Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Hyperfractionated radiation therapy for gliomas of the brainstem in children and in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Experience with twice-a-day fractionation in clinical radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

The RBE for renal damage after irradiation with 3 MeV neutrons

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Therapeutic gain factors for fractionated radiation treatment of spontaneous murine tumors using fast neutrons, photons plus O2(1) or 3 ATA, or photons plus misonidazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Further experience with radiotherapy by multiple daily sessions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Late results of multiple fractions per day (MFD) with misonidazole in advanced cancer of the head and neck. A pilot study of the EORTC radiotherapy group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Radiotherapy of the rhabdomyosarcoma R1H of the rat: kinetics of cellular inactivation by fractionated irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Twice-a-day radiation therapy for supraglottic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

5-Fluorouracil infusions and fractionated doses of radiation: studies with a murine squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Hyperfractionated radiotherapy in the treatment of squamous cell carcinomas of the supraglottic larynx

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Cell Cycle Redistribution as a Factor in Multifraction Irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

1 reference

7 January 2021

A new isoeffect curve for change in dose per fraction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

The EORTC hyperfractionation trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Linear-quadratic model underestimates sparing effect of small doses per fraction in rat spinal cord

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Effect of small doses per fraction in rat spinal cord: influence of initial vs. final top-up doses

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Radiotherapy of the rhabdomyosarcoma R1H of the rat: the influence of the number of fractions on tumor and skin response

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Radiotherapy of the rhabdomyosarcoma R1H of the rat: recovery from radiation injury in tumour and skin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

Inoperable non-small cell lung cancer: a retrospective analysis of 427 patients treated with high-dose radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

The effect of anaesthetics on blood perfusion in transplanted mouse tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2897%2901911-7

7 January 2021

10.1016/S0167-8140(97)01911-7

Identifiers

DOI

1 reference

1 October 2017

1 reference